MX2007013982A - Uso de peptidos derivados del factor de crecimiento amp-18 para el tratamiento de la mucositis. - Google Patents

Uso de peptidos derivados del factor de crecimiento amp-18 para el tratamiento de la mucositis.

Info

Publication number: MX2007013982A
Authority: MX; Mexico
Prior art keywords: peptide; protein; mucositis; amp77; administration
Prior art date: 2005-05-10

Application number

MX2007013982A

Other languages

English (en)

Spanish (es)

Inventor

F Gary Toback

Original Assignee

Univ Chicago

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-05-10

Filing date

2006-05-09

Publication date

2008-03-13

2005-05-10 Priority claimed from EP05010217A external-priority patent/EP1595547A3/fr

2006-05-09 Application filed by Univ Chicago filed Critical Univ Chicago

2006-05-09 Priority claimed from PCT/US2006/018014 external-priority patent/WO2006122162A2/fr

2008-03-13 Publication of MX2007013982A publication Critical patent/MX2007013982A/es

Links

108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 179
102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 50
238000011282 treatment Methods 0.000 title claims description 31
206010028116 Mucosal inflammation Diseases 0.000 title abstract description 67
201000010927 Mucositis Diseases 0.000 title abstract description 67
239000003102 growth factor Substances 0.000 title description 11
101710205777 Gastrokine-1 Proteins 0.000 claims abstract description 75
102100035965 Gastrokine-1 Human genes 0.000 claims abstract description 75
239000000203 mixture Substances 0.000 claims abstract description 20
230000001934 delay Effects 0.000 claims abstract description 3
108090000623 proteins and genes Proteins 0.000 claims description 62
102000004169 proteins and genes Human genes 0.000 claims description 62
230000005855 radiation Effects 0.000 claims description 29
239000008194 pharmaceutical composition Substances 0.000 claims description 18
208000003265 stomatitis Diseases 0.000 claims description 17
238000002512 chemotherapy Methods 0.000 claims description 14
125000003275 alpha amino acid group Chemical group 0.000 claims description 13
206010028980 Neoplasm Diseases 0.000 claims description 12
201000011510 cancer Diseases 0.000 claims description 12
238000002560 therapeutic procedure Methods 0.000 claims description 12
238000001959 radiotherapy Methods 0.000 claims description 11
230000037396 body weight Effects 0.000 claims description 7
239000003937 drug carrier Substances 0.000 claims description 6
238000007920 subcutaneous administration Methods 0.000 claims description 5
238000001990 intravenous administration Methods 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 4
238000007912 intraperitoneal administration Methods 0.000 claims description 3
238000007911 parenteral administration Methods 0.000 claims description 3
238000011200 topical administration Methods 0.000 claims description 3
230000000699 topical effect Effects 0.000 claims 1
238000000034 method Methods 0.000 abstract description 18
241000124008 Mammalia Species 0.000 abstract description 9
101001075218 Homo sapiens Gastrokine-1 Proteins 0.000 abstract description 6
102000049676 human GKN1 Human genes 0.000 abstract description 6
238000011275 oncology therapy Methods 0.000 abstract description 6
210000004027 cell Anatomy 0.000 description 65
235000018102 proteins Nutrition 0.000 description 59
230000000694 effects Effects 0.000 description 32
210000002919 epithelial cell Anatomy 0.000 description 30
235000001014 amino acid Nutrition 0.000 description 23
230000006378 damage Effects 0.000 description 21
229940024606 amino acid Drugs 0.000 description 19
150000001413 amino acids Chemical class 0.000 description 19
241000699666 Mus <mouse, genus> Species 0.000 description 17
241000699670 Mus sp. Species 0.000 description 17
241000699800 Cricetinae Species 0.000 description 15
210000001035 gastrointestinal tract Anatomy 0.000 description 15
241001465754 Metazoa Species 0.000 description 14
239000000284 extract Substances 0.000 description 14
230000006870 function Effects 0.000 description 14
230000002297 mitogenic effect Effects 0.000 description 14
230000001413 cellular effect Effects 0.000 description 13
230000012010 growth Effects 0.000 description 13
208000025865 Ulcer Diseases 0.000 description 12
210000000981 epithelium Anatomy 0.000 description 12
239000013598 vector Substances 0.000 description 12
102000003940 Occludin Human genes 0.000 description 11
108090000304 Occludin Proteins 0.000 description 11
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 11
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 11
210000004877 mucosa Anatomy 0.000 description 11
239000002953 phosphate buffered saline Substances 0.000 description 11
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 11
230000015572 biosynthetic process Effects 0.000 description 10
201000010099 disease Diseases 0.000 description 10
230000002496 gastric effect Effects 0.000 description 10
210000001578 tight junction Anatomy 0.000 description 10
239000003981 vehicle Substances 0.000 description 10
102400001368 Epidermal growth factor Human genes 0.000 description 9
101800003838 Epidermal growth factor Proteins 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
238000004458 analytical method Methods 0.000 description 9
229940116977 epidermal growth factor Drugs 0.000 description 9
239000002609 medium Substances 0.000 description 9
210000002105 tongue Anatomy 0.000 description 9
108010076504 Protein Sorting Signals Proteins 0.000 description 8
239000003226 mitogen Substances 0.000 description 8
210000002784 stomach Anatomy 0.000 description 8
230000001225 therapeutic effect Effects 0.000 description 8
210000001519 tissue Anatomy 0.000 description 8
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 7
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
210000004692 intercellular junction Anatomy 0.000 description 7
230000004048 modification Effects 0.000 description 7
238000012986 modification Methods 0.000 description 7
230000001681 protective effect Effects 0.000 description 7
231100000397 ulcer Toxicity 0.000 description 7
206010015150 Erythema Diseases 0.000 description 6
238000004113 cell culture Methods 0.000 description 6
210000002808 connective tissue Anatomy 0.000 description 6
231100000321 erythema Toxicity 0.000 description 6
108020004707 nucleic acids Proteins 0.000 description 6
102000039446 nucleic acids Human genes 0.000 description 6
150000007523 nucleic acids Chemical group 0.000 description 6
238000011084 recovery Methods 0.000 description 6
230000002829 reductive effect Effects 0.000 description 6
230000008439 repair process Effects 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
230000024883 vasodilation Effects 0.000 description 6
102000003972 Fibroblast growth factor 7 Human genes 0.000 description 5
108090000385 Fibroblast growth factor 7 Proteins 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
208000022559 Inflammatory bowel disease Diseases 0.000 description 5
230000008901 benefit Effects 0.000 description 5
230000010261 cell growth Effects 0.000 description 5
239000002299 complementary DNA Substances 0.000 description 5
206010020718 hyperplasia Diseases 0.000 description 5
230000003993 interaction Effects 0.000 description 5
230000000968 intestinal effect Effects 0.000 description 5
239000010410 layer Substances 0.000 description 5
239000003550 marker Substances 0.000 description 5
230000001590 oxidative effect Effects 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
238000000746 purification Methods 0.000 description 5
210000004203 pyloric antrum Anatomy 0.000 description 5
230000009467 reduction Effects 0.000 description 5
230000004936 stimulating effect Effects 0.000 description 5
230000000638 stimulation Effects 0.000 description 5
230000008719 thickening Effects 0.000 description 5
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 4
206010020649 Hyperkeratosis Diseases 0.000 description 4
230000001154 acute effect Effects 0.000 description 4
125000000217 alkyl group Chemical group 0.000 description 4
238000003556 assay Methods 0.000 description 4
239000011575 calcium Substances 0.000 description 4
229910052791 calcium Inorganic materials 0.000 description 4
238000010367 cloning Methods 0.000 description 4
238000004624 confocal microscopy Methods 0.000 description 4
230000001186 cumulative effect Effects 0.000 description 4
210000000805 cytoplasm Anatomy 0.000 description 4
239000003814 drug Substances 0.000 description 4
238000011156 evaluation Methods 0.000 description 4
238000005194 fractionation Methods 0.000 description 4
238000003119 immunoblot Methods 0.000 description 4
208000015181 infectious disease Diseases 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
210000004962 mammalian cell Anatomy 0.000 description 4
239000000463 material Substances 0.000 description 4
238000013508 migration Methods 0.000 description 4
230000004682 mucosal barrier function Effects 0.000 description 4
239000007800 oxidant agent Substances 0.000 description 4
230000028327 secretion Effects 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
238000012360 testing method Methods 0.000 description 4
FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 3
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 3
241000701022 Cytomegalovirus Species 0.000 description 3
230000006820 DNA synthesis Effects 0.000 description 3
241000588724 Escherichia coli Species 0.000 description 3
108010070675 Glutathione transferase Proteins 0.000 description 3
102100029100 Hematopoietic prostaglandin D synthase Human genes 0.000 description 3
241000282412 Homo Species 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
206010030216 Oesophagitis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
240000004808 Saccharomyces cerevisiae Species 0.000 description 3
244000292604 Salvia columbariae Species 0.000 description 3
235000012377 Salvia columbariae var. columbariae Nutrition 0.000 description 3
235000001498 Salvia hispanica Nutrition 0.000 description 3
230000004888 barrier function Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
125000004432 carbon atom Chemical group C* 0.000 description 3
235000014167 chia Nutrition 0.000 description 3
230000007423 decrease Effects 0.000 description 3
238000012217 deletion Methods 0.000 description 3
230000037430 deletion Effects 0.000 description 3
229940079593 drug Drugs 0.000 description 3
230000007613 environmental effect Effects 0.000 description 3
239000001963 growth medium Substances 0.000 description 3
230000035876 healing Effects 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
210000004201 immune sera Anatomy 0.000 description 3
229940042743 immune sera Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
208000002551 irritable bowel syndrome Diseases 0.000 description 3
210000001985 kidney epithelial cell Anatomy 0.000 description 3
239000011159 matrix material Substances 0.000 description 3
230000001404 mediated effect Effects 0.000 description 3
230000001181 motogenic effect Effects 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 3
230000004792 oxidative damage Effects 0.000 description 3
239000011347 resin Substances 0.000 description 3
229920005989 resin Polymers 0.000 description 3
239000000523 sample Substances 0.000 description 3
239000007929 subcutaneous injection Substances 0.000 description 3
238000010254 subcutaneous injection Methods 0.000 description 3
239000000126 substance Substances 0.000 description 3
238000006467 substitution reaction Methods 0.000 description 3
231100000419 toxicity Toxicity 0.000 description 3
230000001988 toxicity Effects 0.000 description 3
241000701447 unidentified baculovirus Species 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
101710194912 18 kDa protein Proteins 0.000 description 2
206010002091 Anaesthesia Diseases 0.000 description 2
102100034808 CCAAT/enhancer-binding protein alpha Human genes 0.000 description 2
108010001857 Cell Surface Receptors Proteins 0.000 description 2
241000282693 Cercopithecidae Species 0.000 description 2
206010009944 Colon cancer Diseases 0.000 description 2
208000001333 Colorectal Neoplasms Diseases 0.000 description 2
101710124086 Envelope protein UL45 Proteins 0.000 description 2
241000206602 Eukaryota Species 0.000 description 2
OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 2
208000007882 Gastritis Diseases 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
101000945515 Homo sapiens CCAAT/enhancer-binding protein alpha Proteins 0.000 description 2
206010058467 Lung neoplasm malignant Diseases 0.000 description 2
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
239000004472 Lysine Substances 0.000 description 2
241000699673 Mesocricetus auratus Species 0.000 description 2
102000015728 Mucins Human genes 0.000 description 2
108010063954 Mucins Proteins 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 2
108091005461 Nucleic proteins Proteins 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
241000235648 Pichia Species 0.000 description 2
206010040047 Sepsis Diseases 0.000 description 2
208000007107 Stomach Ulcer Diseases 0.000 description 2
IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
239000000654 additive Substances 0.000 description 2
230000000996 additive effect Effects 0.000 description 2
150000001408 amides Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
230000037005 anaesthesia Effects 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
230000000975 bioactive effect Effects 0.000 description 2
230000004071 biological effect Effects 0.000 description 2
210000005178 buccal mucosa Anatomy 0.000 description 2
244000309466 calf Species 0.000 description 2
125000002843 carboxylic acid group Chemical group 0.000 description 2
230000012292 cell migration Effects 0.000 description 2
238000007385 chemical modification Methods 0.000 description 2
239000003795 chemical substances by application Substances 0.000 description 2
206010009887 colitis Diseases 0.000 description 2
230000000112 colonic effect Effects 0.000 description 2
210000004922 colonic epithelial cell Anatomy 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000004132 cross linking Methods 0.000 description 2
239000003085 diluting agent Substances 0.000 description 2
238000009826 distribution Methods 0.000 description 2
239000002552 dosage form Substances 0.000 description 2
238000001493 electron microscopy Methods 0.000 description 2
238000010828 elution Methods 0.000 description 2
230000003628 erosive effect Effects 0.000 description 2
208000006881 esophagitis Diseases 0.000 description 2
210000003238 esophagus Anatomy 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000013604 expression vector Substances 0.000 description 2
210000002950 fibroblast Anatomy 0.000 description 2
102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
230000001744 histochemical effect Effects 0.000 description 2
230000002209 hydrophobic effect Effects 0.000 description 2
238000010348 incorporation Methods 0.000 description 2
CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
210000002490 intestinal epithelial cell Anatomy 0.000 description 2
238000007918 intramuscular administration Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
201000005202 lung cancer Diseases 0.000 description 2
208000020816 lung neoplasm Diseases 0.000 description 2
238000012423 maintenance Methods 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
102000006240 membrane receptors Human genes 0.000 description 2
230000005012 migration Effects 0.000 description 2
108091005601 modified peptides Proteins 0.000 description 2
239000000178 monomer Substances 0.000 description 2
229940051875 mucins Drugs 0.000 description 2
210000003097 mucus Anatomy 0.000 description 2
230000036407 pain Effects 0.000 description 2
239000000816 peptidomimetic Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
230000003389 potentiating effect Effects 0.000 description 2
239000000047 product Substances 0.000 description 2
230000035755 proliferation Effects 0.000 description 2
230000001737 promoting effect Effects 0.000 description 2
238000012797 qualification Methods 0.000 description 2
108020003175 receptors Proteins 0.000 description 2
102000005962 receptors Human genes 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000002356 single layer Substances 0.000 description 2
239000002904 solvent Substances 0.000 description 2
239000000725 suspension Substances 0.000 description 2
239000003053 toxin Substances 0.000 description 2
231100000765 toxin Toxicity 0.000 description 2
108700012359 toxins Proteins 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
230000036269 ulceration Effects 0.000 description 2
230000004584 weight gain Effects 0.000 description 2
235000019786 weight gain Nutrition 0.000 description 2
230000004580 weight loss Effects 0.000 description 2
230000029663 wound healing Effects 0.000 description 2
CXNPLSGKWMLZPZ-GIFSMMMISA-N (2r,3r,6s)-3-[[(3s)-3-amino-5-[carbamimidoyl(methyl)amino]pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2h-pyran-2-carboxylic acid Chemical compound O1[C@@H](C(O)=O)[C@H](NC(=O)C[C@@H](N)CCN(C)C(N)=N)C=C[C@H]1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-GIFSMMMISA-N 0.000 description 1
TVZRAEYQIKYCPH-UHFFFAOYSA-N 3-(trimethylsilyl)propane-1-sulfonic acid Chemical compound C[Si](C)(C)CCCS(O)(=O)=O TVZRAEYQIKYCPH-UHFFFAOYSA-N 0.000 description 1
102000007469 Actins Human genes 0.000 description 1
108010085238 Actins Proteins 0.000 description 1
208000009304 Acute Kidney Injury Diseases 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108010025188 Alcohol oxidase Proteins 0.000 description 1
102100036826 Aldehyde oxidase Human genes 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
241001367049 Autographa Species 0.000 description 1
241000193738 Bacillus anthracis Species 0.000 description 1
231100000699 Bacterial toxin Toxicity 0.000 description 1
101100407060 Caenorhabditis elegans par-6 gene Proteins 0.000 description 1
241000282465 Canis Species 0.000 description 1
102000011068 Cdc42 Human genes 0.000 description 1
108050001278 Cdc42 Proteins 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
206010009900 Colitis ulcerative Diseases 0.000 description 1
241000699802 Cricetulus griseus Species 0.000 description 1
235000004035 Cryptotaenia japonica Nutrition 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
150000008574 D-amino acids Chemical class 0.000 description 1
239000011665 D-biotin Substances 0.000 description 1
SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
206010058839 Enteritis infectious Diseases 0.000 description 1
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
101150031828 F2RL2 gene Proteins 0.000 description 1
108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
101000993347 Gallus gallus Ciliary neurotrophic factor Proteins 0.000 description 1
206010056663 Gastric infection Diseases 0.000 description 1
102400000921 Gastrin Human genes 0.000 description 1
108010052343 Gastrins Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
101000928314 Homo sapiens Aldehyde oxidase Proteins 0.000 description 1
101000817237 Homo sapiens Protein ECT2 Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
108010058683 Immobilized Proteins Proteins 0.000 description 1
206010061598 Immunodeficiency Diseases 0.000 description 1
108090000723 Insulin-Like Growth Factor I Proteins 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
241000235058 Komagataella pastoris Species 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
108010041955 MAP-kinase-activated kinase 2 Proteins 0.000 description 1
101710141347 Major envelope glycoprotein Proteins 0.000 description 1
206010028034 Mouth ulceration Diseases 0.000 description 1
206010028124 Mucosal ulceration Diseases 0.000 description 1
241001529936 Murinae Species 0.000 description 1
108010021466 Mutant Proteins Proteins 0.000 description 1
102000008300 Mutant Proteins Human genes 0.000 description 1
102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
238000007126 N-alkylation reaction Methods 0.000 description 1
108010038807 Oligopeptides Proteins 0.000 description 1
102000015636 Oligopeptides Human genes 0.000 description 1
208000025157 Oral disease Diseases 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
238000012408 PCR amplification Methods 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
101150027732 Pard3 gene Proteins 0.000 description 1
208000037273 Pathologic Processes Diseases 0.000 description 1
208000008469 Peptic Ulcer Diseases 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000007079 Peptide Fragments Human genes 0.000 description 1
108010033276 Peptide Fragments Proteins 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
239000004365 Protease Substances 0.000 description 1
102100040437 Protein ECT2 Human genes 0.000 description 1
102100021538 Protein kinase C zeta type Human genes 0.000 description 1
108091034057 RNA (poly(A)) Proteins 0.000 description 1
208000033626 Renal failure acute Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
229920002684 Sepharose Polymers 0.000 description 1
241000256251 Spodoptera frugiperda Species 0.000 description 1
108091081024 Start codon Proteins 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
102000007641 Trefoil Factors Human genes 0.000 description 1
235000015724 Trifolium pratense Nutrition 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
201000006704 Ulcerative Colitis Diseases 0.000 description 1
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
108010004977 Vasopressins Proteins 0.000 description 1
102000002852 Vasopressins Human genes 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
150000001242 acetic acid derivatives Chemical class 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000002378 acidificating effect Effects 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
108010045606 actin kinase Proteins 0.000 description 1
230000009471 action Effects 0.000 description 1
230000009798 acute exacerbation Effects 0.000 description 1
201000011040 acute kidney failure Diseases 0.000 description 1
208000012998 acute renal failure Diseases 0.000 description 1
230000010933 acylation Effects 0.000 description 1
238000005917 acylation reaction Methods 0.000 description 1
-1 alkyl amide Chemical class 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000029936 alkylation Effects 0.000 description 1
238000005804 alkylation reaction Methods 0.000 description 1
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
229910052782 aluminium Inorganic materials 0.000 description 1
230000003321 amplification Effects 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940121363 anti-inflammatory agent Drugs 0.000 description 1
239000002260 anti-inflammatory agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
239000000427 antigen Substances 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
229960001230 asparagine Drugs 0.000 description 1
235000009582 asparagine Nutrition 0.000 description 1
230000003305 autocrine Effects 0.000 description 1
238000000211 autoradiogram Methods 0.000 description 1
239000000688 bacterial toxin Substances 0.000 description 1
210000004082 barrier epithelial cell Anatomy 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
102000023732 binding proteins Human genes 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000008827 biological function Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
CXNPLSGKWMLZPZ-UHFFFAOYSA-N blasticidin-S Natural products O1C(C(O)=O)C(NC(=O)CC(N)CCN(C)C(N)=N)C=CC1N1C(=O)N=C(N)C=C1 CXNPLSGKWMLZPZ-UHFFFAOYSA-N 0.000 description 1
238000009835 boiling Methods 0.000 description 1
238000010322 bone marrow transplantation Methods 0.000 description 1
210000004899 c-terminal region Anatomy 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
230000004663 cell proliferation Effects 0.000 description 1
230000033077 cellular process Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
239000002738 chelating agent Substances 0.000 description 1
230000009920 chelation Effects 0.000 description 1
AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
238000000546 chi-square test Methods 0.000 description 1
150000001860 citric acid derivatives Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
210000001608 connective tissue cell Anatomy 0.000 description 1
230000030944 contact inhibition Effects 0.000 description 1
230000008878 coupling Effects 0.000 description 1
238000010168 coupling process Methods 0.000 description 1
238000005859 coupling reaction Methods 0.000 description 1
238000011461 current therapy Methods 0.000 description 1
ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
230000009089 cytolysis Effects 0.000 description 1
238000012303 cytoplasmic staining Methods 0.000 description 1
210000000172 cytosol Anatomy 0.000 description 1
230000006240 deamidation Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
230000035622 drinking Effects 0.000 description 1
208000000718 duodenal ulcer Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000002900 effect on cell Effects 0.000 description 1
239000003792 electrolyte Substances 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000003480 eluent Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
230000004890 epithelial barrier function Effects 0.000 description 1
210000005081 epithelial layer Anatomy 0.000 description 1
230000007717 exclusion Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
238000001914 filtration Methods 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000012737 fresh medium Substances 0.000 description 1
201000006585 gastric adenocarcinoma Diseases 0.000 description 1
210000002599 gastric fundus Anatomy 0.000 description 1
210000001156 gastric mucosa Anatomy 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
239000011521 glass Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
LXJXRIRHZLFYRP-UHFFFAOYSA-N glyceraldehyde 3-phosphate Chemical compound O=CC(O)COP(O)(O)=O LXJXRIRHZLFYRP-UHFFFAOYSA-N 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000007952 growth promoter Substances 0.000 description 1
238000011553 hamster model Methods 0.000 description 1
201000010536 head and neck cancer Diseases 0.000 description 1
208000014829 head and neck neoplasm Diseases 0.000 description 1
230000036541 health Effects 0.000 description 1
208000035861 hematochezia Diseases 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
230000001329 hyperkeratotic effect Effects 0.000 description 1
238000010166 immunofluorescence Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000001976 improved effect Effects 0.000 description 1
230000006872 improvement Effects 0.000 description 1
229960000905 indomethacin Drugs 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
238000003780 insertion Methods 0.000 description 1
230000037431 insertion Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
230000005865 ionizing radiation Effects 0.000 description 1
238000002955 isolation Methods 0.000 description 1
239000007951 isotonicity adjuster Substances 0.000 description 1
229940065223 kepivance Drugs 0.000 description 1
230000003780 keratinization Effects 0.000 description 1
210000002510 keratinocyte Anatomy 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
150000003951 lactams Chemical class 0.000 description 1
230000003902 lesion Effects 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000008176 lyophilized powder Substances 0.000 description 1
229920002521 macromolecule Polymers 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
230000035800 maturation Effects 0.000 description 1
210000004379 membrane Anatomy 0.000 description 1
239000012528 membrane Substances 0.000 description 1
238000001000 micrograph Methods 0.000 description 1
230000003278 mimic effect Effects 0.000 description 1
230000004678 mucosal integrity Effects 0.000 description 1
230000035772 mutation Effects 0.000 description 1
230000003533 narcotic effect Effects 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
239000000346 nonvolatile oil Substances 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
235000015097 nutrients Nutrition 0.000 description 1
230000005789 organism growth Effects 0.000 description 1
230000008520 organization Effects 0.000 description 1
230000003076 paracrine Effects 0.000 description 1
230000009054 pathological process Effects 0.000 description 1
230000037361 pathway Effects 0.000 description 1
208000011906 peptic ulcer disease Diseases 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
235000021317 phosphate Nutrition 0.000 description 1
150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
230000001766 physiological effect Effects 0.000 description 1
230000035790 physiological processes and functions Effects 0.000 description 1
239000013612 plasmid Substances 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
238000003752 polymerase chain reaction Methods 0.000 description 1
235000015277 pork Nutrition 0.000 description 1
239000011591 potassium Substances 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000002243 precursor Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000037452 priming Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000002062 proliferating effect Effects 0.000 description 1
125000006239 protecting group Chemical group 0.000 description 1
235000004252 protein component Nutrition 0.000 description 1
108010050991 protein kinase C zeta Proteins 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000004850 protein–protein interaction Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
230000008929 regeneration Effects 0.000 description 1
238000011069 regeneration method Methods 0.000 description 1
230000000284 resting effect Effects 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
230000002441 reversible effect Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
210000004739 secretory vesicle Anatomy 0.000 description 1
238000004062 sedimentation Methods 0.000 description 1
238000000926 separation method Methods 0.000 description 1
238000012163 sequencing technique Methods 0.000 description 1
239000004017 serum-free culture medium Substances 0.000 description 1
230000019491 signal transduction Effects 0.000 description 1
231100000161 signs of toxicity Toxicity 0.000 description 1
150000003384 small molecules Chemical class 0.000 description 1
210000004894 snout Anatomy 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000006641 stabilisation Effects 0.000 description 1
238000011105 stabilization Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000011476 stem cell transplantation Methods 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
239000012134 supernatant fraction Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
230000002194 synthesizing effect Effects 0.000 description 1
210000004876 tela submucosa Anatomy 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
230000036964 tight binding Effects 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
238000001890 transfection Methods 0.000 description 1
238000003146 transient transfection Methods 0.000 description 1
230000005945 translocation Effects 0.000 description 1
230000032258 transport Effects 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
238000011144 upstream manufacturing Methods 0.000 description 1
229960003726 vasopressin Drugs 0.000 description 1
230000035899 viability Effects 0.000 description 1
230000003612 virological effect Effects 0.000 description 1
239000008215 water for injection Substances 0.000 description 1
BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
229960001600 xylazine Drugs 0.000 description 1

Landscapes

Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)

MX2007013982A 2005-05-10 2006-05-09 Uso de peptidos derivados del factor de crecimiento amp-18 para el tratamiento de la mucositis. MX2007013982A (es)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP05010217A EP1595547A3 (fr)	2004-05-11	2005-05-10	Utilisation du facteur de croissance AMP pour le traitement des lésions gastrointestinales et de la insuffisance renale aigue
US79017706P	2006-04-07	2006-04-07
PCT/US2006/018014 WO2006122162A2 (fr)	2005-05-10	2006-05-09	Procede et composition pour traiter la mucosite

Publications (1)

Publication Number	Publication Date
MX2007013982A true MX2007013982A (es)	2008-03-13

Family

ID=40140138

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MX2007013982A MX2007013982A (es)	2005-05-10	2006-05-09	Uso de peptidos derivados del factor de crecimiento amp-18 para el tratamiento de la mucositis.

Country Status (4)

Country	Link
JP (2)	JP5058980B2 (fr)
AT (1)	ATE526983T1 (fr)
CA (1)	CA2643736C (fr)
MX (1)	MX2007013982A (fr)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6734289B2 (en) *	2001-03-29	2004-05-11	The University Of Chicago	Gastrokines and derived peptides including inhibitors
US7629317B2 (en) *	2001-03-29	2009-12-08	The University Of Chicago	Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors

2006
- 2006-05-09 CA CA2643736A patent/CA2643736C/fr not_active Expired - Fee Related
- 2006-05-09 MX MX2007013982A patent/MX2007013982A/es active IP Right Grant
- 2006-05-09 AT AT06770157T patent/ATE526983T1/de not_active IP Right Cessation
- 2006-05-09 JP JP2008511298A patent/JP5058980B2/ja not_active Expired - Fee Related
2011
- 2011-11-30 JP JP2011262746A patent/JP2012046547A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
ATE526983T1 (de)	2011-10-15
JP2012046547A (ja)	2012-03-08
CA2643736A1 (fr)	2006-11-16
CA2643736C (fr)	2015-06-23
JP2008544959A (ja)	2008-12-11
JP5058980B2 (ja)	2012-10-24

Legal Events

Date	Code	Title	Description
2011-10-03	FG	Grant or registration

Publication	Publication Date	Title
EP1895005B1 (fr)	2017-07-26	Inhibiteurs peptidiques à perméabilité cellulaire du processus de transduction du signal de JNK
ES2529196T3 (es)	2015-02-17	Secuencias de nucleótidos y proteínas de genes Nogo y métodos basados en estas
JP5405105B2 (ja)	2014-02-05	グルカゴン様ペプチド−２（ｇｌｐ−２）アナログ
KR102373603B1 (ko)	2022-03-14	섬유증 억제 활성을 가지는 펩티드 및 이를 포함하는 조성물
EP1776958B1 (fr)	2008-12-17	Inhibiteurs peptidiques à permeabilité cellulaire, du mecanisme de transduction du signal de JNK
US8741838B2 (en)	2014-06-03	Control of growth and repair of gastro-intestinal tissues by gastrokines and inhibitors
US20120148590A1 (en)	2012-06-14	Cell-permeable peptide inhibitors of the jnk signal transduction pathway
KR20120082909A (ko)	2012-07-24	합성 마이오스타틴 펩티드 길항제
KR20140099526A (ko)	2014-08-12	안구 건조증의 치료를 위한 jnk 신호 전달 경로의 세포-투과성 펩타이드 억제자의 용도
JP3013896B2 (ja)	2000-02-28	ヒトマンガンスーパーオキシドジスムターゼを含む薬剤組成物
CN114805540A (zh)	2022-07-29	长效肾上腺髓质素衍生物
CN108440668A (zh)	2018-08-24	Fgf21与igf-1的融合蛋白及其应用
ES2753381T3 (es)	2020-04-08	Miméticos de apolipoproteína y usos de los mismos
AU2006244080B2 (en)	2011-09-08	Use of peptides derived from the growth factor AMP-18 for the treatment of mucositis
ES2332882T3 (es)	2010-02-15	Control de crecimiento y reparacion de tejidos gastrointestinales por gastroquinas.
EP3604538A1 (fr)	2020-02-05	Dérivé d'adrénomédulline à durée d'action longue
US8017576B2 (en)	2011-09-13	Methods and compositions to treat mucositis
EP1885390B1 (fr)	2011-10-05	Utilisation des derivees du facteur de croissance amp-18 pour le traitement de la stomatitis
AU2004233911A1 (en)	2004-11-11	Combined use of keratinocyte growth factor agonists and gastrin compounds
CA2643736C (fr)	2015-06-23	Procede et composition pour traiter la mucosite
KR102758046B1 (ko)	2025-01-23	궤양성 대장염 예방 또는 치료용 재조합 단백질 및 이를 포함하는 궤양성 대장염 예방 또는 치료용 조성물
WO2000066721A9 (fr)	2001-08-02	Reduction de la masse adipeuse par modification de l'activite du gene rsk2
EP2696886A2 (fr)	2014-02-19	Protéine-12 apparentée à c1q/tnf et ses compositions et procédés d'utilisation
HK1114123A (en)	2008-10-24	Cell-permeable peptide inhibitors of the jnk signal transduction pathway
HK1098961B (en)	2009-04-03	Cell-permeable peptide inhibitors of the jnk signal transduction pathway